abrdn Healthcare Investors (NYSE:HQH) Reaches New 12-Month High – Here’s Why

abrdn Healthcare Investors (NYSE:HQH)’s share price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $23.15 and last traded at $23.0920, with a volume of 228437 shares trading hands. The stock had previously closed at $23.04.

abrdn Healthcare Investors Stock Performance

The company’s 50-day simple moving average is $20.94 and its 200 day simple moving average is $19.80.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in HQH. Royal Bank of Canada increased its stake in abrdn Healthcare Investors by 22.0% during the first quarter. Royal Bank of Canada now owns 529,826 shares of the financial services provider’s stock worth $8,604,000 after acquiring an additional 95,441 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of abrdn Healthcare Investors in the 1st quarter valued at approximately $166,000. NewEdge Advisors LLC lifted its stake in shares of abrdn Healthcare Investors by 3.0% in the 1st quarter. NewEdge Advisors LLC now owns 43,233 shares of the financial services provider’s stock valued at $702,000 after purchasing an additional 1,274 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of abrdn Healthcare Investors by 7.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 11,732 shares of the financial services provider’s stock worth $191,000 after purchasing an additional 788 shares during the period. Finally, Invesco Ltd. boosted its holdings in shares of abrdn Healthcare Investors by 59.8% in the 2nd quarter. Invesco Ltd. now owns 74,168 shares of the financial services provider’s stock worth $1,149,000 after purchasing an additional 27,768 shares during the period. Institutional investors own 32.60% of the company’s stock.

About abrdn Healthcare Investors

abrdn Healthcare Investors (NYSE:HQH) is a closed-end management investment company that seeks long-term capital appreciation and current income by investing primarily in equity securities of companies operating in the healthcare sector. The fund’s portfolio generally comprises a diversified mix of domestic and international healthcare issuers, spanning pharmaceuticals, biotechnology, medical devices, healthcare services, and related industries.

The fund employs a fundamental, research-driven approach to select investments, focusing on companies with strong balance sheets, innovative product pipelines and the potential for sustainable revenue growth.